SEC Tracker
Get the app
TENX · XBRL financial data

Tenax Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TENX's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers—————year only00*0*0*00*
Research and development1,0661,699*2,6762,3283,1124,594*5,6836,12110,32810,540*11,53912,850
Selling, general and administrative———————5,671———5,934
General and administrative1,0521,642*1,2331,3441,5072,701*5,6555,6716,4785,909*5,034—
Total operating expenses2,1173,341*3,9083,6724,6197,295*11,33811,79216,80616,449*16,57318,784
Operating income (loss)2,1173,341*(3,908)3,6724,619(31,693)*(11,338)(11,792)(16,806)(16,449)*(16,573)(18,784)
Interest expense52*896(0)*00*0*0*——
Other income (expense)0(484)*(117)(1)02*0(9)(15)(9)*(4)0
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)1,9723,226*3,7993,5763,960(28,937)*(10,408)(10,847)(15,804)(15,540)*(15,716)(17,803)
Earnings per share, basic USD per share——(3.12)(1.83)(0.19)—(0.28)(0.27)(0.40)(0.38)*(0.35)(0.35)
Earnings per share, diluted USD per share——(3.12)(1.83)(0.19)—(0.28)(0.27)(0.40)(0.38)*(0.35)(0.35)
Weighted average shares, basic thousands of shares——1,2191,95821,161—36,58539,57239,74140,917*45,22650,869
Weighted average shares, diluted thousands of shares——1,2191,95821,161—36,58539,57239,74140,917*45,22650,869
  • † Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (TENX's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents11,1419,80012,5499,38498,31194,900111,400105,50099,40097,600118,800118,000
Prepaid and other current assets—————1,835—3953,441———
Total current assets11,88311,68414,45910,61699,78496,686112,059105,857102,810104,227123,178121,663
Property and equipment, net50——————————
Right-of-use asset00——————————
Total assets11,88911,68514,46010,61799,78596,686112,059105,857102,810104,227123,178121,663
Accounts payable1352,0731,0818701,5843,1571,8395625,6086,0416,3466,795
Accrued liabilities2931,0125365929781,5369291,9659911,1152,1401,278
Total current liabilities6023,5872,0311,7412,5624,6932,7682,5276,5997,1568,4868,073
Total deposits——11,6008,90097,600———————
Lease liability, non-current00——————————
Total liabilities6023,5872,0311,7412,5624,6932,7682,5276,5997,1568,4868,073
Accumulated deficit(294,027)(297,253)(301,052)(304,627)(308,588)(314,855)(325,263)(336,110)(351,914)(367,454)(383,170)(400,973)
Total stockholders' equity11,2878,09812,4308,87697,22391,993109,291103,33096,21197,071114,692113,590
Total liabilities and equity11,88911,68514,46010,61799,78596,686112,059105,857102,810104,227123,178121,663
Common shares outstanding (cover page) thousands of shares23,8621,9581,9583,4093,4093,9704,1484,5636,24417,19826,52537,424
  • † Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (TENX's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)1,9723,226*3,7993,5763,960(28,937)*(10,408)(10,847)(15,804)(15,540)*(15,716)(17,803)
Stock-based compensation—year only11922*14*970*4,1424,609*5,622*4,790*2,8383,330*
Net cash from operating activities(2,081)*(1,175)*(5,166)(3,031)*(3,087)*(3,527)*(6,967)(6,263)*(9,155)*(13,415)*(9,309)(14,150)*
Net cash from investing activities0*0*00*0*0*00*0*———
Net cash from financing activities(171)*(174)*7,923(134)*92,014*67*23,563278*3,062*11,611*30,49913,371*
  • † Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Tenax Therapeutics118,0000*(14,150)*37.4M8.3 quarters 10-QJun 30, 2026
Aytu Biopharma26,30816,106*4,406*10.9M— 10-KJun 30, 2026
Nanoviricides2,794not reported(2,122)*25.5M1.3 quarters 10-KJun 30, 2026
Lisata Therapeutics10,4430(2,649)*9.0M3.9 quarters 10-QJun 30, 2026
Dyadic International1,425961(1,818)*36.4M1.7 quarters 10-QJun 30, 2026
Kala Bio229not reported(1,535)*19.3M4.7 quarters 10-QJun 30, 2026
Lexaria Bioscience3,5000(1,635)*24.8M2.2 quarters 10-QMay 31, 2026
Curis5,0730(9,646)*2.1M0.5 quarters 10-QJun 30, 2026
Marimed8,43741,9252,219*403.0M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.